<p>，/PRNewswire/ -- 归创通桥医疗科技有限公司（香港交易所代码：2190，&#34;归创通桥&#34;或&#34;公司&#34;）今天公布了截至 2025 年 12 月 31 日的年度业绩。</p>
<p>在 2025 年，公司实现了又一年的强劲增长，盈利能力显著改善。收入同比增长 35.1%，达到人民币 10.6 亿元，而净利润同比增长 143.7%，达到人民币 2.44 亿元。增长得益于核心产品的持续商业势头、国际业务的快速增长以及运营效率的进一步提升。</p>
<p>公司的神经血管介入业务实现收入人民币 6.76 亿元，同比增长 28.0%；而外周血管介入的收入同比增长 50.3%，达到人民币 3.79 亿元。来自中国大陆以外市场的收入达到人民币 4865 万元，同比增长 115.5%，反映了国际市场准入和渠道扩展的持续进展。</p>
<p>尽管中国的量价采购政策持续影响，归创通桥在 2025 年仍保持了 72.1% 的毛利率，并报告非国际财务报告准则调整后的净利润为人民币 2.73 亿元，反映出随着业务规模的扩大，运营杠杆的改善。截至报告期末，包括现金及现金等价物、定期存款和以公允价值计量的金融资产在内的可用财务资源总额达到人民币 26 亿元。</p>
<p>在稳健的运营表现和强大的流动性支持下，公司提议 2025 年每股派发最终股息人民币 0.22 元（含税），派息比例约为 30%。在 2025 年，公司回购了总价值超过 1.3 亿港元的股份，未来计划进一步扩大回购规模，以提升股东回报。</p>
<p>归创通桥通过持续的商业化和创新，继续巩固其长期增长基础。其销售网络现已覆盖中国超过 3300 家医院，产品的累计临床使用量已超过 110 万件。在这一年中，多个差异化产品实现商业化，包括 ZYLOX Mammoth™大口径取栓导管、FALCO™栓塞辅助支架和 Brivix™血管闭合装置（胶原蛋白）。此外，包括 ZYLOX Otter™取栓导管和 ZYLOX Orca™气囊扩张覆盖支架在内的四款产品被纳入国家药品监督管理局的创新医疗器械特别审查程序，进一步丰富了公司的创新管线。</p>
<p>截至本公告日，公司已建立了 79 个产品的管线，其中 61 个已获得国家药品监督管理局批准进行商业化。</p>
<p>全球扩张在 2025 年继续加速。归创通桥的国际商业网络现已覆盖 80 多个国家和地区，包括全球前 10 大医疗器械市场中的七个。公司在 40 个国家和地区实现了 29 个产品的商业化，同时还有超过 50 个产品在 34 个国家和地区进行注册。国际收入以 84% 的四年复合年增长率增长，进一步巩固了公司的国际业务作为一个日益重要的长期增长驱动力。</p>
<p>为了进一步支持其全球化战略，公司于 2026 年 1 月宣布对德国 Optimed Medizinische Instrumente GmbH 进行战略投资。该投资预计将增强归创通桥在欧洲的存在，加速创新产品的国际商业化，并通过中国和德国之间的协同效应提升其全球运营和交付能力。</p>
<p>展望未来，归创通桥将继续执行创新和全球化的双重优先事项。公司将继续扩展其临床差异化产品的管线，加速国际市场准入和商业化，并加强其全球运营平台，以推动长期可持续的盈利增长。</p>
<p><strong>关于归创通桥</strong></p>
<p>归创通桥医疗科技有限公司（&#34;归创通桥&#34;，香港交易所代码：2190）是一家致力于血管介入领域医疗器械的创新研发、制造和商业化的医疗科技公司。公司成立于 2012 年，总部位于中国杭州。</p>
<p>作为一家拥有内部研发和制造能力、专有技术平台和强大商业化能力的综合医疗器械公司，归创通桥秉持&#34;创新提升生活质量&#34;的品牌理念。公司致力于为患者提供高质量、可及的医疗器械和服务，使更多人受益于改善的生活质量。</p>
<p>欲了解更多信息，请访问我们的官方网站 https://www.zyloxtb.com/。</p>
<p>来源：归创通桥</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzE3Jk5ld3NJdGVtSWQ9Q04xMjMyNyZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMTcxMjE4UFJfTkVXU19VU1BSX19fX19DTjEyMzI3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzE3Jk5ld3NJdGVtSWQ9Q04xMjMyNyZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMTcxMjE4UFJfTkVXU19VU1BSX19fX19DTjEyMzI3"/></p>

归创通桥

<p>归创通桥医疗科技有限公司公布了 2025 年度业绩，收入同比增长 35.1%，达到人民币 10.6 亿元，净利润增长 143.7%，达到人民币 2.44 亿元。增长主要得益于核心产品的强劲表现和国际扩张。公司保持了 72.1% 的毛利率，并提议每股派发最终股息人民币 0.22 元。归创通桥专注于创新和全球化，拥有 79 个产品的研发管线，并在德国的 Optimed Medizinische Instrumente GmbH 进行战略投资，以增强其在欧洲的市场存在</p>

<p>, /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, &#34;Zylox-Tonbridge&#34; or the &#34;Company&#34;) today announced its annual results for the year ended December 31, 2025.</p>
<div class="lb-trans"><p>，/PRNewswire/ -- 归创通桥医疗科技有限公司（香港交易所代码：2190，&#34;归创通桥&#34;或&#34;公司&#34;）今天公布了截至 2025 年 12 月 31 日的年度业绩。</p>
</div><p>In 2025, the Company delivered another year of strong growth and materially improved profitability. Revenue rose 35.1% year-over-year to RMB 1.06 billion, while net profit increased 143.7% year-over-year to RMB 244 million. Growth was driven by continued commercial momentum across core products, rapid growth in international business, and further improvement in operating efficiency.</p>
<div class="lb-trans"><p>在 2025 年，公司实现了又一年的强劲增长，盈利能力显著改善。收入同比增长 35.1%，达到人民币 10.6 亿元，而净利润同比增长 143.7%，达到人民币 2.44 亿元。增长得益于核心产品的持续商业势头、国际业务的快速增长以及运营效率的进一步提升。</p>
</div><p>The Company's neurovascular intervention business generated revenue of RMB 676 million, up 28.0% year-over-year, while revenue from peripheral vascular intervention increased 50.3% year-over-year to RMB 379 million. Revenue from markets outside Mainland China reached RMB 48.65 million, up 115.5% year-over-year, reflecting continued progress in international market access and channel expansion.</p>
<div class="lb-trans"><p>公司的神经血管介入业务实现收入人民币 6.76 亿元，同比增长 28.0%；而外周血管介入的收入同比增长 50.3%，达到人民币 3.79 亿元。来自中国大陆以外市场的收入达到人民币 4865 万元，同比增长 115.5%，反映了国际市场准入和渠道扩展的持续进展。</p>
</div><p>Despite the continued impact of volume-based procurement in China, Zylox-Tonbridge maintained a gross margin of 72.1% in 2025 and reported non-IFRS adjusted net profit of RMB 273 million, reflecting improving operating leverage as the business scaled. As of the end of the reporting period, total available financial resources, including cash and cash equivalents, term deposits and financial assets measured at fair value through profit or loss, amounted to RMB 2.60 billion.</p>
<div class="lb-trans"><p>尽管中国的量价采购政策持续影响，归创通桥在 2025 年仍保持了 72.1% 的毛利率，并报告非国际财务报告准则调整后的净利润为人民币 2.73 亿元，反映出随着业务规模的扩大，运营杠杆的改善。截至报告期末，包括现金及现金等价物、定期存款和以公允价值计量的金融资产在内的可用财务资源总额达到人民币 26 亿元。</p>
</div><p>Supported by its solid operating performance and strong liquidity position, the Company proposed a final dividend of RMB 0.22 per share (tax inclusive) for 2025, representing a payout ratio of approximately 30%. In 2025, the Company repurchased shares with an aggregate value of more than HK$130 million, and going forward, it intends to further increase the scale of share repurchases to enhance shareholder returns.</p>
<div class="lb-trans"><p>在稳健的运营表现和强大的流动性支持下，公司提议 2025 年每股派发最终股息人民币 0.22 元（含税），派息比例约为 30%。在 2025 年，公司回购了总价值超过 1.3 亿港元的股份，未来计划进一步扩大回购规模，以提升股东回报。</p>
</div><p>Zylox-Tonbridge continued to strengthen its long-term growth foundation through ongoing commercialization and innovation. Its sales network now covers more than 3,300 hospitals in China, and cumulative clinical use of its products has exceeded 1.1 million units. During the year, several differentiated products were commercialized, including the ZYLOX Mammoth™ Large-Bore Thrombectomy Catheter, FALCO™ Embolization Assist Stent, and Brivix™ Vascular Closure Device (Collagen). In addition, four products, including ZYLOX Otter™ Thrombectomy Catheter and ZYLOX Orca™ Balloon Expandable Covered Stent, were included in the NMPA's Special Review Procedure for Innovative Medical Devices, further enriching the Company's innovation pipeline.</p>
<div class="lb-trans"><p>归创通桥通过持续的商业化和创新，继续巩固其长期增长基础。其销售网络现已覆盖中国超过 3300 家医院，产品的累计临床使用量已超过 110 万件。在这一年中，多个差异化产品实现商业化，包括 ZYLOX Mammoth™大口径取栓导管、FALCO™栓塞辅助支架和 Brivix™血管闭合装置（胶原蛋白）。此外，包括 ZYLOX Otter™取栓导管和 ZYLOX Orca™气囊扩张覆盖支架在内的四款产品被纳入国家药品监督管理局的创新医疗器械特别审查程序，进一步丰富了公司的创新管线。</p>
</div><p>As of the date of this announcement, the Company had built a pipeline of 79 products, including 61 approved by the NMPA for commercialization.</p>
<div class="lb-trans"><p>截至本公告日，公司已建立了 79 个产品的管线，其中 61 个已获得国家药品监督管理局批准进行商业化。</p>
</div><p>Global expansion continued to accelerate in 2025. Zylox-Tonbridge's international commercial network now spans more than 80 countries and regions, including seven of the world's top 10 medical device markets. The Company has commercialized 29 products in 40 countries and regions, while more than 50 products are undergoing registration in 34 countries and regions. International revenue has grown at a four-year CAGR of 84%, reinforcing the Company's international business as an increasingly important long-term growth driver.</p>
<div class="lb-trans"><p>全球扩张在 2025 年继续加速。归创通桥的国际商业网络现已覆盖 80 多个国家和地区，包括全球前 10 大医疗器械市场中的七个。公司在 40 个国家和地区实现了 29 个产品的商业化，同时还有超过 50 个产品在 34 个国家和地区进行注册。国际收入以 84% 的四年复合年增长率增长，进一步巩固了公司的国际业务作为一个日益重要的长期增长驱动力。</p>
</div><p>To further support its globalization strategy, the Company has announced the strategic investment in Germany-based Optimed Medizinische Instrumente GmbH in January 2026. The investment is expected to strengthen Zylox-Tonbridge's presence in Europe, accelerate the international commercialization of innovative products, and enhance its global operations and delivery capabilities through synergies between its China and Germany.</p>
<div class="lb-trans"><p>为了进一步支持其全球化战略，公司于 2026 年 1 月宣布对德国 Optimed Medizinische Instrumente GmbH 进行战略投资。该投资预计将增强归创通桥在欧洲的存在，加速创新产品的国际商业化，并通过中国和德国之间的协同效应提升其全球运营和交付能力。</p>
</div><p>Looking ahead, Zylox-Tonbridge will continue to execute on its dual priorities of innovation and globalization. The Company will continue to expand its pipeline of clinically differentiated products, accelerate international market access and commercialization, and strengthen its global operating platform to drive sustainable, profitable growth over the long term.</p>
<div class="lb-trans"><p>展望未来，归创通桥将继续执行创新和全球化的双重优先事项。公司将继续扩展其临床差异化产品的管线，加速国际市场准入和商业化，并加强其全球运营平台，以推动长期可持续的盈利增长。</p>
</div><p><strong>About Zylox-Tonbridge</strong></p>
<div class="lb-trans"><p><strong>关于归创通桥</strong></p>
</div><p>Zylox-Tonbridge Medical Technology Co., Ltd. (&#34;Zylox-Tonbridge&#34;, HKEX: 2190) is a medical technology company dedicated to the innovative research and development, manufacturing and commercialization of medical devices in the field of vascular intervention. Founded in 2012, the Company is headquartered in Hangzhou, China.</p>
<div class="lb-trans"><p>归创通桥医疗科技有限公司（&#34;归创通桥&#34;，香港交易所代码：2190）是一家致力于血管介入领域医疗器械的创新研发、制造和商业化的医疗科技公司。公司成立于 2012 年，总部位于中国杭州。</p>
</div><p>As an integrated medical device company supported by in-house R&amp;D and manufacturing capabilities, proprietary technology platforms and strong commercialization capabilities, Zylox-Tonbridge adheres to the brand philosophy of &#34;Innovation for Quality Life&#34;. The Company is committed to providing patients with high-quality, accessible medical devices and services, enabling more people to benefit from the improved quality of life.</p>
<div class="lb-trans"><p>作为一家拥有内部研发和制造能力、专有技术平台和强大商业化能力的综合医疗器械公司，归创通桥秉持&#34;创新提升生活质量&#34;的品牌理念。公司致力于为患者提供高质量、可及的医疗器械和服务，使更多人受益于改善的生活质量。</p>
</div><p>For more information, please visit our official website at https://www.zyloxtb.com/.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问我们的官方网站 https://www.zyloxtb.com/。</p>
</div><p>SOURCE ZYLOX-TONBRIDGE</p>
<div class="lb-trans"><p>来源：归创通桥</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzE3Jk5ld3NJdGVtSWQ9Q04xMjMyNyZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMTcxMjE4UFJfTkVXU19VU1BSX19fX19DTjEyMzI3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN12327&amp;Transmission_Id=202603171218PR_NEWS_USPR_____CN12327&amp;DateId=20260317"/></p>

12:18 ET 归创通桥公布 2025 年年度业绩，收入超过人民币 10.6 亿元，净利润同比增长 143.7%